Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx) | Prof John Crown at ECC 2015 - 101271

Spotlight
Video

Results and impact of TAILORx: Trial Assigning IndividuaLized Options for Treatment (Rx) | Prof John Crown at ECC 2015

EMJ has 458 videos Subscribe Here

Loading........
Description: At the European Cancer Congress (ECC) 2015, John Crown, MD, MBA, of St Vincent’s University Hospital, Dublin, Ireland, discusses the low-risk registry results from Trial Assigning IndividuaLized Options for Treatment (TAILORx). TAILORx is a prospective phase 3 clinical trial designed to evaluate the role of endocrine therapy and chemoendocrine therapy in patients with oestrogen receptor (ER)-positive, HER2-negative, node-negative breast cancer whose treatment was guided by the Oncotype DX® Breast Cancer Assay Recurrence Score® results. The results showed that adding genomic information provided by the Oncotype DX® Breast Cancer Assay may influence the selection of patients for adjuvant chemotherapy based on standard clinicopathological criteria.

This content is supported by Genomic Health, Inc.

–––

European Medical Journal

Website: http://emjreviews.com/...
Twitter: https://twitter.com/EMJRevi...
Facebook: https://www.facebook.com/em...
Shared By : EMJ
Posted on : 10/05/15
Added : 2 years ago
Category : Breast Cancer



Recommended

Nothing found.

More From EMJ

Nothing found.